Jarushka Naidoo: Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Jarushka Naidoo shared a post on X:

“Ph III KN867 trial of SBRT+concurrent/adjuvant pembrolizumab stopped early due to higher Adverse Evets in IO arm, and lack of EFS and OS benefit Important negative data, that will inform optimum timing of IO, and definitive treatment modality

Lets see the data.”

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.